Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC

NCT02395250 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT02395250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02395250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC
Lead sponsor
RenJi Hospital
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2015
Completion date
November 30, 2018
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma